| Targets | Partner | Discovery | Preclincal | Phase 1 | Phase 2 | |
PRS-342/BOS-342 |
4-1BB/GPC3 |  |
✓ | ✓ | ✓ |
Pieris and Boston Pharmaceuticals Immuno-Oncology Collaboration
Boston Pharmaceuticals has exclusively licensed worldwide rights to PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology Anticalin®-antibody bispecific fusion protein. Boston Pharmaceuticals is responsible for further development of the program and the program is currently in a phase 1 clinical study.
Pipeline Chart
Immuno-Oncology
Candidate
PRS-342/BOS-342
TARGETS
4-1BB/GPC3
PARTNER
PHASE 1
In Progress
Candidate
PRS-346/SGN-BB228
TARGETS
4-1BB/CD228
PARTNER
PHASE 1
In Progress
Candidate
Candidate Seagen Programs‡
TARGETS
n.d.
PARTNER
DISCOVERY
In Progress